Journal
INTERNATIONAL JOURNAL OF ONCOLOGY
Volume 42, Issue 5, Pages 1605-1612Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/ijo.2013.1843
Keywords
triptolide; oxidative stress; endoplasmic reticulum stress; ERK; breast cancer; apoptosis
Categories
Funding
- National Medical Research Council of Singapore through IRG [NMRC/1109/2007]
Ask authors/readers for more resources
Since its isolation from Tripterygium wilfordii in 1972, triptolide has been shown to possess potent anticancer activity against a variety of cancers, and has entered phase I clinical trial. It is a diterpenoid triepoxide that acts through multiple molecular targets and signaling pathways. The mitogen-activated protein kinases are well known for their modulation of cell survival and proliferation. In particular, the ERK pathway has a dual role in cell proliferation and cell death. Thus far, data on the effect of triptolide on ERK signaling remain limited. In our current study, we have shown for the first time that ERK activation rather than inhibition occurred in a dose- and time-dependent manner following triptolide treatment in MDA-MB-231 breast cancer cells. ERK activation was crucial in mediating triptolide-induced caspase-dependent apoptosis. Tritpolide-induced ERK activation modulated the expression of the Bcl-2 protein family member Bax but was not involved in the downregulation of Bcl-xL expression. Signals acted upstream of ERK activation included generation of reactive oxygen species (ROS) and endoplasmic reticulum stress predominantly via the PERK-eIF2 alpha pathway, as the MEK inhibitor U0126 did not inhibit the phosphorylation of PERK and eIF2 alpha or the generation of ROS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available